Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × Pluvicto × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 39 Metastatic Castration-resistant Prostate Cancer 5 Prostatic Diseases 3 Kidney Neoplasms 3 Urogenital Neoplasms 2 Neoplasms by Site 2 Neoplasms 2 Genital Neoplasms, Male 2 Carcinoma, Renal Cell 2 Prostatic Neoplasms, Castration-Resistant 1 Prostate Cancer Metastatic 1 PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1 Neoplasm Metastasis 1 Metastatic Hormone Naive Prostate Cancer 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Metastatic Castration Resistant Prostate Cancer 1 Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1 Male Urogenital Diseases 1 Genital Diseases, Male 1 Disease 1 Clear-cell metastatic renal cell carcinoma 1

Interventions

Docetaxel 31 pembrolizumab 28 Nivolumab 23 Prednisone 19 enzalutamide 18 Cyclophosphamide 14 aldesleukin 13 Interleukin-2 13 Gemcitabine 13 Sunitinib 12 Zoledronic Acid 11 Specimen Handling 11 Radiosurgery 11 Bevacizumab 11 Androgen Antagonists 10 Abiraterone Acetate 10 pazopanib 9 fludarabine 9 Sorafenib 9 Magnetic Resonance Spectroscopy 9 Ipilimumab 9 Everolimus 9 abiraterone 8 Radiotherapy 8 Paclitaxel 8 avelumab 7 Doxorubicin 7 Biopsy 7 cabazitaxel 6 Prednisolone 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03392428 2022-06-13

TheraP

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Phase 2 Completed

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡